Response by Jia et al to Letter Regarding Article, "high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study"

Xiaoming Jia; Wensheng Sun; Ron C. Hoogeveen; Vijay Nambi; Kunihiro Matsushita; Aaron R. Folsom; Gerardo Heiss; David J. Couper; Scott D. Solomon; Eric Boerwinkle; Amil Shah; Elizabeth Selvin; James A. De Lemos; Christie M. Ballantyne

doi:10.1161/CIRCULATIONAHA.119.043149

Response by Jia et al to Letter Regarding Article, "high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study"

Xiaoming Jia, Wensheng Sun, Ron C. Hoogeveen, Vijay Nambi, Kunihiro Matsushita, Aaron R. Folsom, Gerardo Heiss, David J. Couper, Scott D. Solomon, Eric Boerwinkle, Amil Shah, Elizabeth Selvin, James A. De Lemos, Christie M. Ballantyne

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	E772-E773
Journal	Circulation
Volume	140
Issue number	20
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.119.043149
State	Published - Nov 12 2019
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIRCULATIONAHA.119.043149

Cite this

Jia, X., Sun, W., Hoogeveen, R. C., Nambi, V., Matsushita, K., Folsom, A. R., Heiss, G., Couper, D. J., Solomon, S. D., Boerwinkle, E., Shah, A., Selvin, E., De Lemos, J. A., & Ballantyne, C. M. (2019). Response by Jia et al to Letter Regarding Article, "high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study". Circulation, 140(20), E772-E773. https://doi.org/10.1161/CIRCULATIONAHA.119.043149

Jia, X, Sun, W, Hoogeveen, RC, Nambi, V, Matsushita, K, Folsom, AR, Heiss, G, Couper, DJ, Solomon, SD, Boerwinkle, E, Shah, A, Selvin, E, De Lemos, JA & Ballantyne, CM 2019, 'Response by Jia et al to Letter Regarding Article, "high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study"', Circulation, vol. 140, no. 20, pp. E772-E773. https://doi.org/10.1161/CIRCULATIONAHA.119.043149

@article{d55a5d99b952474fa4941a7af6613689,

title = "Response by Jia et al to Letter Regarding Article, {"}high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study{"}",

author = "Xiaoming Jia and Wensheng Sun and Hoogeveen, {Ron C.} and Vijay Nambi and Kunihiro Matsushita and Folsom, {Aaron R.} and Gerardo Heiss and Couper, {David J.} and Solomon, {Scott D.} and Eric Boerwinkle and Amil Shah and Elizabeth Selvin and {De Lemos}, {James A.} and Ballantyne, {Christie M.}",

note = "Funding Information: Drs Nambi, Ballantyne, and Hoogeveen are coinventors on a provisional patent (patent #61721475) titled “Biomarkers to Improve Prediction of Heart Failure Risk,” filed by Roche Diagnostics and Baylor College of Medicine on their behalf. Dr Matsushita reports nonfinancial support from Roche Diagnostics outside the submitted work. Dr Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, BMS, Celladon, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, Novartis, Sanofi Pasteur, and Theracos and has consulted for Akros, Alnylam, Amgen, AoBiome, AstraZeneca, Bayer, BMS, Cardiac Dimensions, Cardurion, Corvia, Gilead, GSK, Ironwood, Janssen, Merck, Novartis, Roche, Quantum Genetics, Takeda, and Theracos. None of these supported the current research. Dr Shah has received research support from Novartis through the Brigham and Women{\textquoteright}s Hospital and consulting fees from GlaxoSmithKline and Philips Ultrasound. Dr de Lemos has received grant support from Abbott Diagnostics and Roche Diagnostics and consulting income from Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel, Inc, Radiometer, and Roche Diagnostics. Dr de Lemons is also coinventor on a patent issued to the University of Maryland using high-sensitivity cardiac troponin T and left ventricular hypertrophy as markers of heart failure risk (patent no. 61990386). Dr Ballantyne is a consultant for Roche Diagnostics and Abbott Diagnostics. Dr. Jia, W. Sun, and Drs Folsom, Heiss, Couper, Boerwinkle, and Selvin have stated that they have no actual or potential perceived conflicts of interests.",

year = "2019",

month = nov,

day = "12",

doi = "10.1161/CIRCULATIONAHA.119.043149",

language = "English (US)",

volume = "140",

pages = "E772--E773",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "20",

}

TY - JOUR

T1 - Response by Jia et al to Letter Regarding Article, "high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study"

AU - Jia, Xiaoming

AU - Sun, Wensheng

AU - Hoogeveen, Ron C.

AU - Nambi, Vijay

AU - Matsushita, Kunihiro

AU - Folsom, Aaron R.

AU - Heiss, Gerardo

AU - Couper, David J.

AU - Solomon, Scott D.

AU - Boerwinkle, Eric

AU - Shah, Amil

AU - Selvin, Elizabeth

AU - De Lemos, James A.

AU - Ballantyne, Christie M.

N1 - Funding Information: Drs Nambi, Ballantyne, and Hoogeveen are coinventors on a provisional patent (patent #61721475) titled “Biomarkers to Improve Prediction of Heart Failure Risk,” filed by Roche Diagnostics and Baylor College of Medicine on their behalf. Dr Matsushita reports nonfinancial support from Roche Diagnostics outside the submitted work. Dr Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, BMS, Celladon, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, Novartis, Sanofi Pasteur, and Theracos and has consulted for Akros, Alnylam, Amgen, AoBiome, AstraZeneca, Bayer, BMS, Cardiac Dimensions, Cardurion, Corvia, Gilead, GSK, Ironwood, Janssen, Merck, Novartis, Roche, Quantum Genetics, Takeda, and Theracos. None of these supported the current research. Dr Shah has received research support from Novartis through the Brigham and Women’s Hospital and consulting fees from GlaxoSmithKline and Philips Ultrasound. Dr de Lemos has received grant support from Abbott Diagnostics and Roche Diagnostics and consulting income from Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel, Inc, Radiometer, and Roche Diagnostics. Dr de Lemons is also coinventor on a patent issued to the University of Maryland using high-sensitivity cardiac troponin T and left ventricular hypertrophy as markers of heart failure risk (patent no. 61990386). Dr Ballantyne is a consultant for Roche Diagnostics and Abbott Diagnostics. Dr. Jia, W. Sun, and Drs Folsom, Heiss, Couper, Boerwinkle, and Selvin have stated that they have no actual or potential perceived conflicts of interests.

PY - 2019/11/12

Y1 - 2019/11/12

UR - http://www.scopus.com/inward/record.url?scp=85074809833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074809833&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.119.043149

DO - 10.1161/CIRCULATIONAHA.119.043149

M3 - Letter

C2 - 31710526

AN - SCOPUS:85074809833

SN - 0009-7322

VL - 140

SP - E772-E773

JO - Circulation

JF - Circulation

IS - 20

ER -

Response by Jia et al to Letter Regarding Article, "high-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study"

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this